Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi reports positive new multiple sclerosis drug trial data

Sanofi reports positive new multiple sclerosis drug trial data

12th July 2011

Sanofi has published positive clinical trial data from the first phase III study of alemtuzumab, a developmental treatment for multiple sclerosis (MS).

The company has participated in a randomised study, Care-MS I, in which the treatment's efficacy was compared to a clinically-approved alternative among patients with relapsing-remitting MS.

It was shown that alemtuzumab was able to deliver a 55 percent reduction in relapse rate compared to the control treatment, thus meeting the primary efficacy endpoint and qualifying the trial as a success.

Another phase III study of the drug – which was developed collaboratively by Sanofi subsidiary Genzyme and Bayer HealthCare – is already underway, with regulatory filings expected in early 2012.

Christopher Viehbacher, chief executive officer for Sanofi, said: "Today's results are an important step forward in the development of alemtuzumab to address the substantial unmet needs for MS patients."

Genzyme has been part of Sanofi since the conclusion of its multibillion-dollar takeover in April 2011.ADNFCR-8000103-ID-800618632-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.